All research presented at ACG 2025 is strictly embargoed until 12:00 pm local Arizona Time, which aligns with Pacific Daylight Time (PDT)/3:00 pm ET on Sunday, October 26, 2025.
Oral 53 – Early Colon Adenoma Development Following Immune Checkpoint Inhibitor Colitis: Implications for Prompt Surveillance Colonoscopy
Tuesday, October 28, 2025 | 3:25 PM – 3:35 PM PDT | North Ballroom 120BC
Author Insight from Tanvi Gupta, MD
What’s new here and important for clinicians?
Our study expands on a prior pilot study to better characterize colon adenoma development following immune checkpoint inhibitor-mediated diarrhea and colitis (IMDC), by examining a larger cohort of 248 patients. We found that patients who develop IMDC have a significantly increased and accelerated risk of adenoma formation within one year of diagnosis, particularly among those with baseline polyps or active histological inflammation. These findings highlight the importance of an earlier, risk-stratified approach to surveillance colonoscopy in this growing patient population.
What do patients need to know?
Immune checkpoint inhibitors are highly effective cancer therapies but can sometimes cause adverse effects such as diarrhea and colitis. Our research shows that patients who develop these side effects may form colon polyps sooner than others. Because some of these polyps can progress to cancer, patients who have had colitis should talk with their doctor about the timing of a follow-up colonoscopy to detect and remove any polyps early, even if they do not have symptoms.
Author Contact
Tanvi Gupta, MD
University of Texas Health Science Center
Houston, TX
tanvi.gupta [at] uth.tmc.edu
For assistance contacting other ACG experts, please contact Becky Abel, ACG’s Senior Communications Manager, at mediaonly [at] gi.org.